Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: N/ADiagnosis: Hematopoietic Stem Cell TransplantNCT ID: NCT02016781
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 13-453
This study is designed as a multicenter trial, with biological assignment to one of two study arms; Arm 1: Reduced intensity conditioning allogeneic hematopoietic cell transplantation (RIC-alloHCT), Arm 2: Non-Transplant Therapy/Best Supportive Care.
Conducting Institutions: Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital
Overall PI: Corey Cutler, MD,
Dana-Farber Cancer Institute
Site-responsible Investigators: Yi-Bin Chen, MD,
Massachusetts General Hospital
Contacts: Dana-Farber Cancer Institute:
email@example.comMassachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100